AGIO Agios Pharmaceuticals Inc.

52.03
-0.24  -0%
Previous Close 52.27
Open 52.56
Price To Book 3.98
Market Cap 3027036512
Shares 58,178,676
Volume 512,782
Short Ratio
Av. Daily Volume 609,938

SEC filingsSee all SEC filings

  1. 8-K - Current report 19512189
  2. 8-K - Current report 181243773
  3. 8-K - Current report 181214033
  4. 8-K - Current report 181189847
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 181152291

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 2H 2019.
AG-348 - Mitapivat
Thalassemia
FDA Approval announced July 20, 2018.
Ivosidenib
IDH1m Relapsed/Refractory AML - cancer
Phase 3 enrolment to be completed 2019.
AG-348 (ACTIVATE)
Pyruvate kinase deficiency
Phase 3 enrolment to be completed 2020.
AG-120 and VIDAZA - AGILE
Frontline Acute myeloid leukemia (AML) harboring an IDH1 mutation - cancer
Global Phase 3 study for AG-221 initiated October 2015. Continues to enroll as of January 2018.
Enasidenib (AG-221) - IDHENTIFY
Refractory Acute myeloid leukemia (AML) - cancer
Approval announced August 1, 2017.
IDHIFA (enasidenib) - AG-221
Advanced hematologic malignancies with an IDH2 mutation
Phase 3 top-line data due 1H 2019.
AG-120 Ivosidenib
IDH1 mutant positive cholangiocarcinoma - cancer
Phase 1 data at ASCO June 2018 noted CR rate was 24%.
AG-120 Ivosidenib
R/R Acute Myeloid Leukemia (AML)
Phase 1/2 updated data at ASCO June 2018. ORR of 78%, CR Rate of 44%.
Enasidenib or ivosidenib with VIDAZA
Frontline AML with IDH1 or IDH2 mutation
Phase 1 updated data at ASH December 2018. CR+CRi/CRp 80%.
Ivosidenib or enasidenib
Frontline AML with IDH1 or IDH2 mutation
Phase 1 dose escalation data due 1H 2019.
AG-270
Solid tumors
Phase 3 trial to be initiated YE 2019.
Vorasidenib (AG-881)
Glioma
sNDA filed 4Q 2018.
Ivosidenib
Frontline AML with IDH1 mutation
Phase 1 data due 1H 2019.
Ivosidenib and Vorasidenib (AG-881)
IDHm low-grade glioma

Latest News

  1. See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.
  2. 5 Biotech Stocks That Could Face M&A Next!
  3. Agios Highlights Key 2019 Initiatives to Broaden Potential for Cancer and Rare Genetic Disease Programs to Build Long-Term Value
  4. Agios to Present at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019
  5. Our Take On Agios Pharmaceuticals, Inc.’s (NASDAQ:AGIO) CEO Salary
  6. Market Trends Toward New Normal in DXC Technology, Patterson Companies, Lumentum, DSW, Agios Pharmaceuticals, and Six Flags Entertainment Corporation New — Emerging Consolidated Expectations, Analyst Ratings
  7. Hedge Funds Are Selling Agios Pharmaceuticals Inc (AGIO)
  8. Today's Research Reports on Trending Tickers: Arrowhead Pharmaceuticals and Agios Pharmaceuticals
  9. Could These Be the Next 2 Biotech Buyouts?
  10. Today's Research Reports on Trending Tickers: Amarin Corporation and Agios Pharmaceuticals
  11. Agios Presents Updated Data from the Ivosidenib Phase 1 Dose-Escalation and Expansion Trial in IDH1 Mutant Positive Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Ineligible for Standard Treatment and Myelodysplastic Syndrome (MDS)
  12. Agios Announces Updated Data from Phase 1 Study of Ivosidenib or Enasidenib in Combination with Standard Induction and Consolidation Chemotherapy in Newly Diagnosed AML Patients With an IDH Mutation
  13. Today's Research Reports on Trending Tickers: Agios Pharmaceuticals and Exelixis
  14. Today's Research Reports on Trending Tickers: Agios Pharmaceuticals and Amarin Corporation
  15. Edited Transcript of AGIO earnings conference call or presentation 1-Nov-18 12:00pm GMT
  16. Agios Presents Updated Data from Phase 1 Dose-Escalation Study of AG-881 in Patients with IDH Mutant Positive Advanced Glioma
  17. Today's Research Reports on Trending Tickers: Exelixis and Agios Pharmaceuticals
  18. New Research Coverage Highlights John B. Sanfilippo & Son, Axcelis Technologies, Cogent Communications, Star Bulk Carriers, Agios Pharmaceuticals, and MDC Partners — Consolidated Revenues, Company Growth, and Expectations for 2018
  19. 3 Biotech Stocks Poised for Big Rebounds

SEC Filings

  1. 8-K - Current report 19512189
  2. 8-K - Current report 181243773
  3. 8-K - Current report 181214033
  4. 8-K - Current report 181189847
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 181152291
  6. 8-K - Current report 181152043
  7. 8-K - Current report 181053864
  8. 8-K - Current report 181053818
  9. CT ORDER - Confidential treatment order 181035919
  10. CT ORDER - Confidential treatment order 181030316